162 related articles for article (PubMed ID: 35702037)
21. Clinical Activity of Ipilimumab in Acral Melanoma: A Retrospective Review.
Johnson DB; Peng C; Abramson RG; Ye F; Zhao S; Wolchok JD; Sosman JA; Carvajal RD; Ariyan CE
Oncologist; 2015 Jun; 20(6):648-52. PubMed ID: 25964307
[TBL] [Abstract][Full Text] [Related]
22. Immune checkpoint inhibitor-based therapy for advanced acral and mucosal melanoma.
Mori T; Izumi T; Doi R; Kamimura A; Takai S; Teramoto Y; Nakamura Y
Exp Dermatol; 2023 Mar; 32(3):276-289. PubMed ID: 36477933
[TBL] [Abstract][Full Text] [Related]
23. Translational pathology, genomics and the development of systemic therapies for acral melanoma.
Chen YA; Teer JK; Eroglu Z; Wu JY; Koomen JM; Karreth FA; Messina JL; Smalley KSM
Semin Cancer Biol; 2020 Apr; 61():149-157. PubMed ID: 31689494
[TBL] [Abstract][Full Text] [Related]
24. Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma.
Buchbinder EI; Sosman JA; Lawrence DP; McDermott DF; Ramaiya NH; Van den Abbeele AD; Linette GP; Giobbie-Hurder A; Hodi FS
Cancer; 2015 Nov; 121(22):4007-15. PubMed ID: 26264378
[TBL] [Abstract][Full Text] [Related]
25. Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172).
Nathan P; Ascierto PA; Haanen J; Espinosa E; Demidov L; Garbe C; Guida M; Lorigan P; Chiarion-Sileni V; Gogas H; Maio M; Fierro MT; Hoeller C; Terheyden P; Gutzmer R; Guren TK; Bafaloukos D; Rutkowski P; Plummer R; Waterston A; Kaatz M; Mandala M; Marquez-Rodas I; Muñoz-Couselo E; Dummer R; Grigoryeva E; Young TC; Schadendorf D
Eur J Cancer; 2019 Sep; 119():168-178. PubMed ID: 31445199
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of transarterial infusion of anti-PD-1 in the treatment of advanced or metastatic acral and mucosal melanomas.
Qianqi C; Yan Z; Yueqiang T; Jiangman D; Xiaohong F; Qiming Z
Cell Mol Biol (Noisy-le-grand); 2022 Feb; 67(5):263-268. PubMed ID: 35818244
[TBL] [Abstract][Full Text] [Related]
27. Clinical and molecular features of subungual melanomas are site-specific and distinct from acral melanomas.
Holman BN; Van Gulick RJ; Amato CM; MacBeth ML; Davies KD; Aisner DL; Robinson WA; Couts KL
Melanoma Res; 2020 Dec; 30(6):562-573. PubMed ID: 33156595
[TBL] [Abstract][Full Text] [Related]
28. Somatic activation of KIT in distinct subtypes of melanoma.
Curtin JA; Busam K; Pinkel D; Bastian BC
J Clin Oncol; 2006 Sep; 24(26):4340-6. PubMed ID: 16908931
[TBL] [Abstract][Full Text] [Related]
29. Prognostic Significance of Subungual Anatomic Site in Acral Lentiginous Melanoma.
Mejbel HA; Torres-Cabala CA; Milton DR; Ivan D; Nagarajan P; Curry JL; Ciurea AM; Rubin AI; Hwu WJ; Prieto VG; Aung PP
Arch Pathol Lab Med; 2021 Aug; 145(8):943-952. PubMed ID: 33290520
[TBL] [Abstract][Full Text] [Related]
30. CCND1 copy number increase and cyclin D1 expression in acral melanoma: a comparative study of fluorescence in situ hybridization and immunohistochemistry in a Chinese cohort.
Liu J; Yu W; Gao F; Qi S; Du J; Ma X; Zhang Y; Zheng J; Su J
Diagn Pathol; 2021 Jul; 16(1):60. PubMed ID: 34225728
[TBL] [Abstract][Full Text] [Related]
31. Clinical and genetic analysis of melanomas arising in acral sites.
Zaremba A; Murali R; Jansen P; Möller I; Sucker A; Paschen A; Zimmer L; Livingstone E; Brinker TJ; Hadaschik E; Franklin C; Roesch A; Ugurel S; Schadendorf D; Griewank KG; Cosgarea I
Eur J Cancer; 2019 Sep; 119():66-76. PubMed ID: 31419753
[TBL] [Abstract][Full Text] [Related]
32. Management of acral lentiginous melanoma: current updates and future directions.
Dugan MM; Perez MC; Karapetyan L; Zager JS
Front Oncol; 2024; 14():1323933. PubMed ID: 38390259
[TBL] [Abstract][Full Text] [Related]
33. Consumption of the epidermis in acral lentiginous melanoma.
Ohata C; Nakai C; Kasugai T; Katayama I
J Cutan Pathol; 2012 Jun; 39(6):577-81. PubMed ID: 22574622
[TBL] [Abstract][Full Text] [Related]
34. Safety of pembrolizumab for the treatment of melanoma.
Martin-Liberal J; Kordbacheh T; Larkin J
Expert Opin Drug Saf; 2015 Jun; 14(6):957-64. PubMed ID: 25927979
[TBL] [Abstract][Full Text] [Related]
35. Getting under the skin: The role of CDK4/6 in melanomas.
Guo L; Qi J; Wang H; Jiang X; Liu Y
Eur J Med Chem; 2020 Oct; 204():112531. PubMed ID: 32712436
[TBL] [Abstract][Full Text] [Related]
36. Adverse events associated with postoperative outcomes of adjuvant anti-PD-1 antibody therapy in both acral and non-acral cutaneous melanomas: A multicenter, observational, post hoc analysis study.
Muto Y; Kambayashi Y; Kato H; Fukushima S; Ito T; Maekawa T; Fujisawa Y; Yoshino K; Uchi H; Matsushita S; Yamamoto Y; Amagai R; Ohuchi K; Hashimoto A; Asano Y; Fujimura T
J Dermatol; 2024 Mar; 51(3):458-462. PubMed ID: 37518979
[TBL] [Abstract][Full Text] [Related]
37. Acral melanoma: clinical advances and hope for the future.
Perez MC; Messina JL; Karapetyan L; Neves RI; Sondak VK
Clin Adv Hematol Oncol; 2023 Aug; 21(8):400-409. PubMed ID: 37530614
[TBL] [Abstract][Full Text] [Related]
38. Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics.
Woodman SE; Davies MA
Biochem Pharmacol; 2010 Sep; 80(5):568-74. PubMed ID: 20457136
[TBL] [Abstract][Full Text] [Related]
39. The Systemic Management of Advanced Melanoma in 2016.
Heppt MV; Dietrich C; Graf SA; Ruzicka T; Tietze JK; Berking C
Oncol Res Treat; 2016; 39(10):635-642. PubMed ID: 27710977
[TBL] [Abstract][Full Text] [Related]
40. The efficacy of anti-programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma.
Ogata D; Haydu LE; Glitza IC; Patel SP; Tawbi HA; McQuade JL; Diab A; Ekmekcioglu S; Wong MK; Davies MA; Amaria RN
Cancer Med; 2021 Apr; 10(7):2293-2299. PubMed ID: 33686688
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
